

Listing of Claims

1. **(original)** An antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding VCC-1, wherein said antisense compound specifically hybridizes with and inhibits the expression of VCC-1.
2. **(original)** The antisense compound of claim 1 which is an antisense oligonucleotide.
3. **(original)** The antisense oligonucleotide of claim 2 comprising a nucleic acid sequence selected from the group consisting of at least eight contiguous bases of SEQ ID NO: 1 – SEQ ID NO: 1099.
4. **(original)** The antisense oligonucleotide of claim 2 comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1 – SEQ ID NO: 1099.
5. **(currently amended)** The antisense compound of claim 2 [**1, 3, or 4**] wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
6. **(original)** The antisense compound of claim 5 wherein the modified internucleoside linkage is a phosphorothioate linkage.
7. **(currently amended)** The antisense compound of claim 2 [**1, 3, or 4**] wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
8. **(original)** The antisense compound of claim 7 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
9. **(currently amended)** The antisense compound of claim 2 [**1, 3, or 4**] wherein the antisense oligonucleotide comprises at least one modified nucleobase.

10. (original) The antisense compound of claim 9 wherein the modified nucleobase is a 5-methylcytosine.

11. (currently amended) The antisense compound of claim 2 [**1, 3, or 4**] wherein the antisense oligonucleotide is a chimeric oligonucleotide.

12. (original) A composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

13. (original) The composition of claim 12 further comprising a colloidal dispersion system.

14. (original) The composition of claim 13 wherein the antisense compound is an antisense oligonucleotide.

15. (original) A method of inhibiting the expression of VCC-1 in cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 1 so that expression of VCC-1 is inhibited.

16. (original) A method of treating a human having a disease or condition associated with VCC-1 comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound of claim 1 so that expression of VCC-1 is inhibited.

17. (currently amended) The method of claim 16 wherein the disease or condition is selected from the group consisting of diabetes, an immunological disorder, a cardiovascular disorder, a neurologic disorder, an ischemia/reperfusion injury, any form of cancer, and an angiogenic disorder.

U.S. Patent Application No. TBA
(§371 Application Based on PCT/US2003/025891)
Preliminary Amendment A
February 18, 2005

Claims 18-21 (canceled)

22. (original) The method of claim 16 wherein the disease or condition is any form of cancer.

23. (original) The method of claim 16 wherein the disease or condition is an angiogenic disorder.